Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Vaccinex Inc (VCNX)

Vaccinex Inc (VCNX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.0800 -0.1900 (-14.96%) 01/17/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 1.0800 unch (unch) 15:37 ET
News & Headlines for Fri, Jan 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards

Vaccinex announces Nasdaq delisting due to non-compliance with equity standards; trading shifts to OTC Markets.Quiver AI SummaryVaccinex, Inc., a clinical-stage biotechnology company focused on treating...

VCNX : 1.0800 (-14.96%)
Vaccinex Announces Receipt of Delisting Notification from Nasdaq

VCNX : 1.0800 (-14.96%)
Vaccinex, Inc. Reports Q3 Financial Results and Advances Alzheimer’s Development While Exploring Partnership Opportunities

Vaccinex reports promising Alzheimer’s treatment results, financial updates, and plans for partnerships to enhance development.Quiver AI SummaryVaccinex, Inc. has reported its financial results for the...

VCNX : 1.0800 (-14.96%)
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

VCNX : 1.0800 (-14.96%)
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

VCNX : 1.0800 (-14.96%)
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

VCNX : 1.0800 (-14.96%)
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

VCNX : 1.0800 (-14.96%)
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

VCNX : 1.0800 (-14.96%)
MarketBeat Week in Review – 2/6 - 2/10

Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely

AI : 32.01 (-0.93%)
BBAI : 3.92 (-5.54%)
PLTR : 71.77 (+3.65%)
SOUN : 13.64 (-2.36%)
MSFT : 429.03 (+1.05%)
ON : 54.63 (+2.09%)
AAPL : 229.98 (+0.75%)
AMZN : 225.94 (+2.39%)
TTWO : 186.41 (+1.66%)
MRK : 97.92 (-2.76%)
VCNX : 1.0800 (-14.96%)
ENPH : 63.69 (+0.35%)
Should Investors Buy or Sell the Vaccinex Patent News?

Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news?

VCNX : 1.0800 (-14.96%)
MRK : 97.92 (-2.76%)

Barchart Exclusives

This Little-Known Dividend Stock Yields 12%. Should You Buy It Now?
This commercial mortgage REIT offers a compelling 12.21% dividend yield and strong growth potential. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Master Swing Trading: Strategies for Momentum and Trends